Courtesy of Dr. Carlos Fava. The real incidence of peripheral artery (PAD) disease in TAVR remains unclear. Different reports still estimate it is between 10 and 46%, but they have shown it has a negative impact in evolution. 51,685 TAVR patients were analyzed. 12,740 of these patients presented PAD (24.6%). PAD patients tended to be<a href="https://solaci.org/en/2019/09/11/the-real-impact-of-peripheral-artery-disease-in-tavr/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best results than clopidogrel. However, nowadays, it is unclear which of them is superior in the long term, taking into account the fact that one starts to<a href="https://solaci.org/en/2019/09/05/esc-2019-isar-react-5-which-is-better-in-acs-prasugrel-or-ticagrelor/" title="Read more" >...</a>
Yet scarce, there is evidence supporting next-day discharge (NDD) after TAVR is safe when patients receiving balloon expandable valves meet certain conditions. This had not yet been shown for self-expandable valves. This study looks into NDD after TAVR by femoral access with self-expandable valves. The authors retrospectively compared all consecutive patients undergoing elective minimalist TAVR<a href="https://solaci.org/en/2019/07/04/next-day-discharge-after-tavr-equally-safe-for-all-prosthesis/" title="Read more" >...</a>
Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients. The VIVA (Valve in Valve) registry, conducted at 23 sites, was a prospective study designed to systematically collect data from patients with degenerated<a href="https://solaci.org/en/2019/06/18/valve-in-valve-with-self-expanding-prosthesis-what-happens-with-gradients-at-one-year/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe at one year. In a follow-up using computerized tomography (TC), hypoattenuated leaflet thickening was observed in a minority of patients, but it did not have a long-term hemodynamic impact. It should be noted that the management strategy for<a href="https://solaci.org/en/2019/06/13/low-risk-tavr-trending-in-all-papers/" title="Read more" >...</a>
Non-adherence to dual antiplatelet therapy varies with age and patients older than 75 years old are those who discontinue treatment most frequently. However, this characteristic in elderly patients was not associated with more cardiovascular events. Treatment compliance protected patients younger than 75 years old from events, while there was increased cardiovascular risk among this population<a href="https://solaci.org/en/2019/06/12/cardiovascular-risk-dual-antiplatelet-therapy-and-age-what-should-we-know/" title="Read more" >...</a>
According to this large global registry, mortality after transcatheter aortic valve replacement (TAVR) is twice as high in nonagenarians as against the “younger” group (90 patients. Additionally, risk scores cannot be trusted given that on the one hand they were designed for patients with planned surgery, and on the other hand, they included few patients<a href="https://solaci.org/en/2019/06/11/safe-for-80-year-olds-should-nonagenarians-be-withheld-from-tavr/" title="Read more" >...</a>
After post TAVR mean 3-year follow-up, a new onset persistent left bundle branch block (LBBB) was not associated with higher mortality or hospitalization for cardiac failure according to this study to be published soon in J Am Coll Cardiol Intv. Nevertheless, LBBB was associated to higher risk of definite pacemaker and a negative impact in<a href="https://solaci.org/en/2019/06/05/post-tavr-new-onset-left-bundle-branch-block-at-long-term-worth-our-attention/" title="Read more" >...</a>
This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials and expands the scope of TAVR. Evidence across the range of risk studied supports a paradigm shift in patients with symptomatic severe aortic stenosis. The clinical superiority of TAVR compared with surgery has been demonstrated across the spectrum<a href="https://solaci.org/en/2019/05/30/europcr-2019-most-recent-tavr-meta-analysis-the-spectrum-of-treatment-reaches-all-patients/" title="Read more" >...</a>
Long-term follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and developed left bundle branch block (LBBB) after the procedure seems reassuring. Although it is not benign, it is associated with more conduction defects, more pacemakers, and worsening ventricular function. Long-term follow-up “partially reassures” the concerns of many physicians about new LBBB after TAVR.<a href="https://solaci.org/en/2019/05/27/europcr-2019-long-term-follow-up-for-new-left-bundle-branch-block-after-tavr-is-reassuring-with-certain-precautions/" title="Read more" >...</a>